2023-12-142024-12-312024-12-31false15351062SAFATHERAPY LTD2025-08-27falseiso4217:GBPxbrli:pure153510622023-12-13153510622024-12-31153510622023-12-142024-12-31153510622023-12-12153510622023-12-13153510622023-12-132023-12-1315351062bus:SmallEntities2023-12-142024-12-3115351062bus:AuditExempt-NoAccountantsReport2023-12-142024-12-3115351062bus:FullAccounts2023-12-142024-12-3115351062bus:PrivateLimitedCompanyLtd2023-12-142024-12-3115351062core:WithinOneYear2024-12-3115351062core:AfterOneYear2024-12-3115351062core:WithinOneYear2023-12-1315351062core:AfterOneYear2023-12-1315351062core:ShareCapital2024-12-3115351062core:SharePremium2024-12-3115351062core:RevaluationReserve2024-12-3115351062core:OtherReservesSubtotal2024-12-3115351062core:RetainedEarningsAccumulatedLosses2024-12-3115351062core:ShareCapital2023-12-1315351062core:SharePremium2023-12-1315351062core:RevaluationReserve2023-12-1315351062core:OtherReservesSubtotal2023-12-1315351062core:RetainedEarningsAccumulatedLosses2023-12-1315351062core:LandBuildings2024-12-3115351062core:PlantMachinery2024-12-3115351062core:Vehicles2024-12-3115351062core:FurnitureFittings2024-12-3115351062core:OfficeEquipment2024-12-3115351062core:NetGoodwill2024-12-3115351062core:IntangibleAssetsOtherThanGoodwill2024-12-3115351062core:ListedExchangeTraded2024-12-3115351062core:UnlistedNon-exchangeTraded2024-12-3115351062core:LandBuildings2023-12-1315351062core:PlantMachinery2023-12-1315351062core:Vehicles2023-12-1315351062core:FurnitureFittings2023-12-1315351062core:OfficeEquipment2023-12-1315351062core:NetGoodwill2023-12-1315351062core:IntangibleAssetsOtherThanGoodwill2023-12-1315351062core:ListedExchangeTraded2023-12-1315351062core:UnlistedNon-exchangeTraded2023-12-1315351062core:LandBuildings2023-12-142024-12-3115351062core:PlantMachinery2023-12-142024-12-3115351062core:Vehicles2023-12-142024-12-3115351062core:FurnitureFittings2023-12-142024-12-3115351062core:OfficeEquipment2023-12-142024-12-3115351062core:NetGoodwill2023-12-142024-12-3115351062core:IntangibleAssetsOtherThanGoodwill2023-12-142024-12-3115351062core:ListedExchangeTraded2023-12-142024-12-3115351062core:UnlistedNon-exchangeTraded2023-12-142024-12-3115351062core:MoreThanFiveYears2023-12-142024-12-3115351062core:Non-currentFinancialInstruments2024-12-3115351062core:Non-currentFinancialInstruments2023-12-1315351062dpl:CostSales2023-12-142024-12-3115351062dpl:DistributionCosts2023-12-142024-12-3115351062core:LandBuildings2023-12-142024-12-3115351062core:PlantMachinery2023-12-142024-12-3115351062core:Vehicles2023-12-142024-12-3115351062core:FurnitureFittings2023-12-142024-12-3115351062core:OfficeEquipment2023-12-142024-12-3115351062dpl:AdministrativeExpenses2023-12-142024-12-3115351062core:NetGoodwill2023-12-142024-12-3115351062core:IntangibleAssetsOtherThanGoodwill2023-12-142024-12-3115351062dpl:GroupUndertakings2023-12-142024-12-3115351062dpl:ParticipatingInterests2023-12-142024-12-3115351062dpl:GroupUndertakingscore:ListedExchangeTraded2023-12-142024-12-3115351062core:ListedExchangeTraded2023-12-142024-12-3115351062dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-12-142024-12-3115351062core:UnlistedNon-exchangeTraded2023-12-142024-12-3115351062dpl:CostSales2023-12-132023-12-1315351062dpl:DistributionCosts2023-12-132023-12-1315351062core:LandBuildings2023-12-132023-12-1315351062core:PlantMachinery2023-12-132023-12-1315351062core:Vehicles2023-12-132023-12-1315351062core:FurnitureFittings2023-12-132023-12-1315351062core:OfficeEquipment2023-12-132023-12-1315351062dpl:AdministrativeExpenses2023-12-132023-12-1315351062core:NetGoodwill2023-12-132023-12-1315351062core:IntangibleAssetsOtherThanGoodwill2023-12-132023-12-1315351062dpl:GroupUndertakings2023-12-132023-12-1315351062dpl:ParticipatingInterests2023-12-132023-12-1315351062dpl:GroupUndertakingscore:ListedExchangeTraded2023-12-132023-12-1315351062core:ListedExchangeTraded2023-12-132023-12-1315351062dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-12-132023-12-1315351062core:UnlistedNon-exchangeTraded2023-12-132023-12-1315351062core:NetGoodwill2024-12-3115351062core:IntangibleAssetsOtherThanGoodwill2024-12-3115351062core:LandBuildings2024-12-3115351062core:PlantMachinery2024-12-3115351062core:Vehicles2024-12-3115351062core:FurnitureFittings2024-12-3115351062core:OfficeEquipment2024-12-3115351062core:AfterOneYear2024-12-3115351062core:WithinOneYear2024-12-3115351062core:ListedExchangeTraded2024-12-3115351062core:UnlistedNon-exchangeTraded2024-12-3115351062core:ShareCapital2024-12-3115351062core:SharePremium2024-12-3115351062core:RevaluationReserve2024-12-3115351062core:OtherReservesSubtotal2024-12-3115351062core:RetainedEarningsAccumulatedLosses2024-12-3115351062core:NetGoodwill2023-12-1315351062core:IntangibleAssetsOtherThanGoodwill2023-12-1315351062core:LandBuildings2023-12-1315351062core:PlantMachinery2023-12-1315351062core:Vehicles2023-12-1315351062core:FurnitureFittings2023-12-1315351062core:OfficeEquipment2023-12-1315351062core:AfterOneYear2023-12-1315351062core:WithinOneYear2023-12-1315351062core:ListedExchangeTraded2023-12-1315351062core:UnlistedNon-exchangeTraded2023-12-1315351062core:ShareCapital2023-12-1315351062core:SharePremium2023-12-1315351062core:RevaluationReserve2023-12-1315351062core:OtherReservesSubtotal2023-12-1315351062core:RetainedEarningsAccumulatedLosses2023-12-1315351062core:NetGoodwill2023-12-1215351062core:IntangibleAssetsOtherThanGoodwill2023-12-1215351062core:LandBuildings2023-12-1215351062core:PlantMachinery2023-12-1215351062core:Vehicles2023-12-1215351062core:FurnitureFittings2023-12-1215351062core:OfficeEquipment2023-12-1215351062core:AfterOneYear2023-12-1215351062core:WithinOneYear2023-12-1215351062core:ListedExchangeTraded2023-12-1215351062core:UnlistedNon-exchangeTraded2023-12-1215351062core:ShareCapital2023-12-1215351062core:SharePremium2023-12-1215351062core:RevaluationReserve2023-12-1215351062core:OtherReservesSubtotal2023-12-1215351062core:RetainedEarningsAccumulatedLosses2023-12-1215351062core:AfterOneYear2023-12-142024-12-3115351062core:WithinOneYear2023-12-142024-12-3115351062core:Non-currentFinancialInstrumentscore:CostValuation2023-12-142024-12-3115351062core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-142024-12-3115351062core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-142024-12-3115351062core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-142024-12-3115351062core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-142024-12-3115351062core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-142024-12-3115351062core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-142024-12-3115351062core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-142024-12-3115351062core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-142024-12-3115351062core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3115351062core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3115351062core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3115351062core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3115351062core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3115351062core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3115351062core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3115351062core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3115351062core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3115351062core:Non-currentFinancialInstrumentscore:CostValuation2023-12-1315351062core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-1315351062core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-1315351062core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-1315351062core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-1315351062core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-1315351062core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-1315351062core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-1315351062core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-1315351062bus:Director12023-12-142024-12-31

SAFATHERAPY LTD

Registered Number
15351062
(England and Wales)

Unaudited Financial Statements for the Period ended
31 December 2024

SAFATHERAPY LTD
Company Information
for the period from 14 December 2023 to 31 December 2024

Director

Mr Muzzammil Patel

Registered Address

128 City Road
London
EC1V 2NX

Registered Number

15351062 (England and Wales)
SAFATHERAPY LTD
Balance Sheet as at
31 December 2024

Notes

2024

£

£

Current assets
Debtors108
Cash at bank and on hand1,038
1,146
Creditors amounts falling due within one year3(4,442)
Net current assets (liabilities)(3,296)
Total assets less current liabilities(3,296)
Net assets(3,296)
Capital and reserves
Called up share capital4
Profit and loss account(3,300)
Shareholders' funds(3,296)
The financial statements were approved and authorised for issue by the Director on 27 August 2025, and are signed on its behalf by:
Mr Muzzammil Patel
Director
Registered Company No. 15351062
SAFATHERAPY LTD
Notes to the Financial Statements
for the period ended 31 December 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
2.Average number of employees

2024
Average number of employees during the year2
3.Creditors: amounts due within one year

2024

£
Bank borrowings and overdrafts4,442
Total4,442
4.Controlling party
The company considers Mr Muzzammil Patel to be its ultimate controlling party.